SLL
Clinical trials for SLL explained in plain language.
Never miss a new study
Get alerted when new SLL trials appear
Sign up with your email to follow new studies for SLL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Tough-to-Treat blood cancers: rocbrutinib takes on pirtobrutinib in Head-to-Head trial
Disease control Recruiting nowThis study tests a new oral drug, rocbrutinib, against another drug, pirtobrutinib, in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or not responded after prior treatment with a BTK inhibitor. About 306 participants …
Matched conditions: SLL
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated May 26, 2026 06:38 UTC
-
New hope for CLL patients: drug combo aims to wipe out hidden cancer cells
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of targeted therapy will get epcor…
Matched conditions: SLL
Phase: PHASE2 • Sponsor: Zulfa Omer • Aim: Disease control
Last updated May 26, 2026 06:32 UTC
-
New hope for Tough-to-Treat blood cancer: drug combo aims to keep disease in check
Disease control Recruiting nowThis study tests whether a new drug, nemtabrutinib, combined with venetoclax works better than the standard venetoclax plus rituximab for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least one prior t…
Matched conditions: SLL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Massive new registry tracks 8,000 blood cancer patients for decades
Knowledge-focused Recruiting nowThis study is a long-term registry that follows up to 8,000 people with chronic lymphocytic leukemia (CLL) and similar blood cancers. It does not test any new treatment but instead collects information on survival and disease course over many years. Participants must be 18 or old…
Matched conditions: SLL
Sponsor: German CLL Study Group • Aim: Knowledge-focused
Last updated May 12, 2026 13:39 UTC